Virus-induced brain pathology and the neuroinflammation-inflammation continuum: the neurochemists view
Authors:
Open Access
- 23 January 2024
- journal article
- research article
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 131 (12) , 1429-1453
Abstract
Fascinatingly, an abundance of recent studies has subscribed to the importance of cytotoxic immune mechanisms that appear to increase the risk/trigger for many progressive neurodegenerative disorders, including Parkinson’s disease (PD), Alzheimer’s disease (AD), amyotrophic lateral sclerosis, and multiple sclerosis. Events associated with the neuroinflammatory cascades, such as ageing, immunologic dysfunction, and eventually disruption of the blood–brain barrier and the “cytokine storm”, appear to be orchestrated mainly through the activation of microglial cells and communication with the neurons. The inflammatory processes prompt cellular protein dyshomeostasis. Parkinson’s and Alzheimer’s disease share a common feature marked by characteristic pathological hallmarks of abnormal neuronal protein accumulation. These Lewy bodies contain misfolded α-synuclein aggregates in PD or in the case of AD, they are Aβ deposits and tau-containing neurofibrillary tangles. Subsequently, these abnormal protein aggregates further elicit neurotoxic processes and events which contribute to the onset of neurodegeneration and to its progression including aggravation of neuroinflammation. However, there is a caveat for exclusively linking neuroinflammation with neurodegeneration, since it’s highly unlikely that immune dysregulation is the only factor that contributes to the manifestation of many of these neurodegenerative disorders. It is unquestionably a complex interaction with other factors such as genetics, age, and environment. This endorses the “multiple hit hypothesis”. Consequently, if the host has a genetic susceptibility coupled to an age-related weakened immune system, this makes them more susceptible to the virus/bacteria-related infection. This may trigger the onset of chronic cytotoxic neuroinflammatory processes leading to protein dyshomeostasis and accumulation, and finally, these events lead to neuronal destruction. Here, we differentiate “neuroinflammation” and “inflammation” with regard to the involvement of the blood–brain barrier, which seems to be intact in the case of neuroinflammation but defect in the case of inflammation. There is a neuroinflammation-inflammation continuum with regard to virus-induced brain affection. Therefore, we propose a staging of this process, which might be further developed by adding blood- and CSF parameters, their stage-dependent composition and stage-dependent severeness grade. If so, this might be suitable to optimise therapeutic strategies to fight brain neuroinflammation in its beginning and avoid inflammation at all.Keywords
Funding Information
- Universitätsklinikum Würzburg
This publication has 279 references indexed in Scilit:
- Neuroprotective Function of DJ-1 in Parkinson’s DiseaseOxidative Medicine and Cellular Longevity, 2013
- ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditionsProceedings of the National Academy of Sciences, 2013
- A Virological View of Innate Immune RecognitionAnnual Review of Microbiology, 2012
- Inhibition of NADPH oxidase promotes alternative and anti‐inflammatory microglial activation during neuroinflammationJournal of Neurochemistry, 2011
- Reactive Glia not only Associates with Plaques but also Parallels Tangles in Alzheimer's DiseaseThe American Journal of Pathology, 2011
- Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic interventionNeurobiology of Disease, 2010
- Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegenerationProceedings of the National Academy of Sciences, 2009
- Janus kinases in immune cell signalingImmunological Reviews, 2009
- Potential Therapeutic Targets for PPARγ after Spinal Cord InjuryPPAR Research, 2008
- Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset FamiliesScience, 1993